Novartis (NOVNEE) Stock Overview
Engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 2/6 |
| Dividends | 5/6 |
NOVNEE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Novartis AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 103.68 |
| 52 Week High | CHF 104.54 |
| 52 Week Low | CHF 81.55 |
| Beta | 0.56 |
| 1 Month Change | 12.11% |
| 3 Month Change | 6.79% |
| 1 Year Change | 4.69% |
| 3 Year Change | 30.20% |
| 5 Year Change | 25.98% |
| Change since IPO | 20,636.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| NOVNEE | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | 2.3% | 3.8% | 1.2% |
| 1Y | 4.7% | 6.9% | 3.7% |
Return vs Industry: NOVNEE underperformed the Swiss Pharmaceuticals industry which returned 6.5% over the past year.
Return vs Market: NOVNEE exceeded the Swiss Market which returned 2.7% over the past year.
Price Volatility
| NOVNEE volatility | |
|---|---|
| NOVNEE Average Weekly Movement | 2.4% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in CH Market | 7.6% |
| 10% least volatile stocks in CH Market | 1.7% |
Stable Share Price: NOVNEE has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: NOVNEE's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 75,883 | Vas Narasimhan | www.novartis.com |
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta.
Novartis AG Fundamentals Summary
| NOVNEE fundamental statistics | |
|---|---|
| Market cap | CHF 201.29b |
| Earnings (TTM) | CHF 10.90b |
| Revenue (TTM) | CHF 44.05b |
Is NOVNEE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOVNEE income statement (TTM) | |
|---|---|
| Revenue | US$55.19b |
| Cost of Revenue | US$13.09b |
| Gross Profit | US$42.10b |
| Other Expenses | US$28.44b |
| Earnings | US$13.65b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 28, 2025
| Earnings per share (EPS) | 7.05 |
| Gross Margin | 76.28% |
| Net Profit Margin | 24.74% |
| Debt/Equity Ratio | 73.2% |
How did NOVNEE perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/05 19:40 |
| End of Day Share Price | 2025/09/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novartis AG is covered by 74 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamla Singh | AlphaValue |
| John Eade | Argus Research Company |
| Fabrizio Spagna | Axia Financial Research |